Literature DB >> 27012631

Apigenin supplementation protects the development of dextran sulfate sodium-induced murine experimental colitis by inhibiting canonical and non-canonical inflammasome signaling pathways.

Yazmín K Márquez-Flores1, Isabel Villegas2, Ana Cárdeno2, M Ángeles Rosillo2, Catalina Alarcón-de-la-Lastra2.   

Abstract

The present study was designed to elucidate the protective effects of dietary apigenin (API) enrichment in a chronic colitis model induced by DSS in mice. Inflammatory mediators and the possible role of canonical and non-canonical NLRP3 inflammasome signaling pathways in the beneficial effects of API under chronic inflammatory conditions were also explored. Six-week-old mice were randomized in four dietary groups: sham and control groups received standard diet (SD), and other two groups were fed with API at 0.1%. After 30days, all groups except sham received 3% DSS in drinking water for 5days followed by a regime of 21days of water. Our results revealed that dietary API supplementation decreased the macroscopic and microscopic damage signs of colitis; also, it was capable to down-regulate mPGES, COX-2 and iNOS enzyme colonic expressions and to decrease serum matrix metalloproteinase (MMP-3) levels. Similarly, API diet reduced IL-1β and TNF-α proinflammatory cytokine secretions in primary LPS-stimulated splenocytes. Furthermore, we demonstrated that API anti-inflammatory activity was related with an inhibition of both canonical and non-canonical NLRP3 inflammasome pathways by decreasing proinflammatory IL-1β and IL-18 cytokine levels as a consequence of regulation of cleaved caspase-1 and caspase-11 enzymes. We conclude that API supplement might provide a basis for developing a new dietary strategy for the prevention of chronic ulcerative colitis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apigenin; DSS; caspases; chronic colitis; inflammasome

Mesh:

Substances:

Year:  2016        PMID: 27012631     DOI: 10.1016/j.jnutbio.2015.12.002

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  15 in total

Review 1.  Inflammasomes and intestinal inflammation.

Authors:  N Zmora; M Levy; M Pevsner-Fishcer; E Elinav
Journal:  Mucosal Immunol       Date:  2017-04-12       Impact factor: 7.313

2.  A dietary flavone confers communicable protection against colitis through NLRP6 signaling independently of inflammasome activation.

Authors:  K Radulovic; S Normand; A Rehman; A Delanoye-Crespin; J Chatagnon; M Delacre; N Waldschmitt; L F Poulin; J Iovanna; B Ryffel; P Rosenstiel; M Chamaillard
Journal:  Mucosal Immunol       Date:  2017-11-15       Impact factor: 7.313

Review 3.  Pharmacological Effects of Polyphenol Phytochemicals on the Intestinal Inflammation via Targeting TLR4/NF-κB Signaling Pathway.

Authors:  Caiyun Yu; Dong Wang; Zaibin Yang; Tian Wang
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

Review 4.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

5.  Anti-Inflammatory Properties of the Enaminone E121 in the Dextran Sulfate Sodium (DSS) Colitis Model.

Authors:  Maitham A Khajah; Kethireddy V Ananthalakshmi; Ivan Edafiogho
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

Review 6.  Therapeutic potential of flavonoids in inflammatory bowel disease: A comprehensive review.

Authors:  Ali Salaritabar; Behrad Darvishi; Farzaneh Hadjiakhoondi; Azadeh Manayi; Antoni Sureda; Seyed Fazel Nabavi; Leo R Fitzpatrick; Seyed Mohammad Nabavi; Anupam Bishayee
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

Review 7.  Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation.

Authors:  Carolina Pellegrini; Luca Antonioli; Gloria Lopez-Castejon; Corrado Blandizzi; Matteo Fornai
Journal:  Front Immunol       Date:  2017-01-25       Impact factor: 7.561

8.  A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation.

Authors:  Carolina Pellegrini; Matteo Fornai; Rocchina Colucci; Laura Benvenuti; Vanessa D’Antongiovanni; Gianfranco Natale; Federica Fulceri; Marta Giorgis; Elisabetta Marini; Simone Gastaldi; Massimo Bertinaria; Corrado Blandizzi; Luca Antonioli
Journal:  Front Pharmacol       Date:  2018-12-03       Impact factor: 5.810

Review 9.  The significant impact of apigenin on different aspects of autoimmune disease.

Authors:  Neda Kasiri; Mahshid Rahmati; Leila Ahmadi; Nahid Eskandari
Journal:  Inflammopharmacology       Date:  2018-09-18       Impact factor: 5.093

10.  MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice.

Authors:  Agampodi Promoda Perera; Ruchira Fernando; Tanvi Shinde; Rohit Gundamaraju; Benjamin Southam; Sukhwinder Singh Sohal; Avril A B Robertson; Kate Schroder; Dale Kunde; Rajaraman Eri
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.